期刊
ALZHEIMERS & DEMENTIA
卷 14, 期 4, 页码 492-501出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2017.11.015
关键词
Alzheimer's disease; Alzheimer's disease dementia; Diagnostic biomarkers; Biomarker combination; Cerebrospinal fluid; Neurofilament light chain; Neurogranin; YKL-40; Pathophysiological pathways; Neurodegeneration; Clinical diagnosis; Cognitive aging; Mild cognitive impairment; Frontotemporal dementia; Precision medicine
资金
- AXA Research Fund
- Fondation Universite Pierre et Marie Curie
- Fondation pour la Recherche sur Alzheimer, Paris, France
- Investissements d'avenir [ANR-10-IAIHU-06]
- Swedish Research Council
- European Research Council
- Medical Research Council (UK)
Introduction: The diagnostic and classificatory performances of all combinations of three core (amyloid beta peptide [i.e., A beta(1-42)], total tau [t-tau], and phosphorylated tau) and three novel (neurofilament light chain protein, neurogranin, and YKL-40) cerebrospinal fluid biomarkers of neurodegeneration were compared among individuals with mild cognitive impairment (n = 41), Alzheimer's disease dementia (ADD; n = 35), frontotemporal dementia (FTD; n = 9), and cognitively healthy controls (HC; n = 21), using 10-fold cross-validation. Methods: The combinations ranking in the top 10 according to diagnostic accuracy in differentiating between distinct diagnostic categories were identified. Results: The single biomarkers or biomarker combinations generating the best area under the receiver operating characteristics (AUROCs) were the following: the combination [amyloid beta peptide + phosphorylated tau + neurofilament light chain] for distinguishing between ADD patients and HC (AUROC = 0.86), t-tau for distinguishing between ADD and FTD patients (AUROC = 0.82), and t-tau for distinguishing between FTD patients and HC (AUROC = 0.78). Conclusions: Novel and established cerebrospinal fluid markers perform with at least fair accuracy in the discrimination between ADD and FTD. The classification of mild cognitive impairment individuals was poor. (C) 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据